Source: Science Daily
While the fight against fatty liver disease continues to challenge the United States and much of the world, driven by rising rates of high-calorie diets and sedentary lifestyles, new hope has emerged in the form of an experimental therapy.
Metabolic dysfunction-associated steatohepatitis (MASH) is a serious and increasingly common form of fatty liver disease linked to obesity and type 2 diabetes. It is a progressive condition that develops when excess fat accumulates in the liver, triggering chronic inflammation and tissue damage. Over time, it can silently advance to cirrhosis, liver failure, or even liver cancer. Because symptoms often do not appear until the disease is advanced, many patients remain undiagnosed.
A new study on ION224, an experimental MASH therapy developed by researchers at the University of California, San Diego School of Medicine, has reported encouraging results. According to findings published in The Lancet, the treatment targets a key liver enzyme involved in fat production and has been shown to significantly improve liver health in patients without requiring major weight loss.
ION224 works by blocking an enzyme called DGAT2, which plays a central role in the liver's production and storage of fat. By inhibiting this pathway, researchers believe the therapy can directly interrupt the disease process at its source, reducing fat buildup and inflammation inside liver cells.
The ongoing clinical trial is currently in Phase IIb and involves 160 adults with MASH and early to moderate fibrosis. In the study, participants received monthly injections of the drug over 51 weeks. Those given higher doses showed the most notable improvements, with around 60% experiencing meaningful gains in liver health compared with the placebo group.
It is worth noting that the treatment did not produce any serious side effects typically associated with the drug, including worsening kidney or liver function. The drug also appeared to be generally well-tolerated. Researchers further highlighted that improvements were observed even in patients who did not experience significant weight loss, suggesting that the therapy may work independently of traditional weight reduction strategies.
Experts say this sets ION224 apart from many existing approaches that primarily focus on managing weight or metabolic risk factors. Instead, the therapy directly targets the biological mechanisms driving fat accumulation in the liver, potentially offering a more precise treatment option.
While the results are promising, researchers emphasize that larger Phase III trials are still needed to confirm both safety and long-term effectiveness before the drug can move closer to regulatory approval.
Ultimately, while there is no better way to combat MASH and its long list of potential complications than eating healthy and maintaining an active lifestyle, the potential of ION224 suggests it could one day be used alongside other metabolic therapies to slow, halt, or even reverse liver damage in patients at risk of advanced disease.
